Iovance Biotherapeutics, Inc. · NASDAQ:IOVA

Iovance Biotherapeutics — Investor Presentation (February 2026)

33 slides from Iovance Biotherapeutics's investor presentation, Feb 24, 2026

  1. Slide 1: Corporate Overview February 2026

    1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview February 2026 1

  2. Slide 2: Forward-Looking Statements

    2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litiga

  3. Slide 3: Global Leadership in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer

    3 © 2026, Iovance Biotherapeutics, Inc. Global Leadership in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer 3 Approved Products Commercial Launch Financials >85 ~$303M Cash as of 12/31/25 Treatment Centers as of 12/31/25* 2 ~95% 50% Gross Margin (Q4 2025) © 2026, Iovance

  4. Slide 4: The Pioneer in One-Time Cell Therapy for Solid Tumors

    4 © 2026, Iovance Biotherapeutics, Inc. The Pioneer in One - Time Cell Therapy for Solid Tumors 4 4 © 2026, Iovance Biotherapeutics, Inc. 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre - Treated Patient Population; 2. Karapetyan et al, Tandem Meeting 2026. Physician - assessed conf

  5. Slide 5: Strong Platform Supports Backbone IO Therapy for Solid Tumors

    5 © 2026, Iovance Biotherapeutics, Inc. Strong Platform Supports Backbone IO Therapy for Solid Tumors Iovance Retains Global Portfolio and Technology Platform Rights Approved Amtagvi Treatment R egimen Canada EU: Updated Submission Planned Australia 1H26 Switzerland 1H27 UK 1H26 U.S. Under Review Ad

  6. Slide 6: Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors

    6 © 2026, Iovance Biotherapeutics, Inc. Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors Unique Mechanism of Action • Individualized • One - time therapy • Patient’s T cells fight cancer Tumor Tissue Collection Patient - specific T Cells Grown into the Billions 1

  7. Slide 7: Market Expansion Opportunity in Solid Tumors

    7 © 2026, Iovance Biotherapeutics, Inc. Global Deaths 2 U.S. Deaths 1 59K 8K Melanoma 1.8M 125K Lung & Bronchus 50K 5K Soft Tissue Sarcomas 97K 13K Endometrial 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. https://seer.cancer.g ov (accessed F

  8. Slide 8: First FDA-approved One-time, Individualized T cell Therapy for a Solid Tumor Cancer

    8 © 2026, Iovance Biotherapeutics, Inc. 8 First FDA - approved One - time, Individualized T cell Therapy for a Solid Tumor Cancer

  9. Slide 9: Advanced Melanoma Market Opportunity

    9 © 2026, Iovance Biotherapeutics, Inc. Significant unmet need in frontline and beyond 1 Advanced Melanoma Market Opportunity 2L+ Advanced Melanoma Population 2,3 US: 8K Potential ex - US Markets: 22 K Overall (1L+): 7 0K BRAF wild - type (prior ICI therapy ) ~ 5 months BRAF mutated (prior ICI and t

  10. Slide 10: Deep and Durable Responses at 5-Year Follow Up

    10 © 2026, Iovance Biotherapeutics, Inc. One Third of Responses Remain Ongoing without Subsequent Treatment 5 Year OS 19.7% mDOR 36.5 Months ORR 31.4% mOS 13.9 Months 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre - Treated Patient Population Abbreviations: mDOR, median duration of

  11. Slide 11: Best-in-class real-world data driving increased Amtagvi adoption

    11 © 2026, Iovance Biotherapeutics, Inc. 52 % ORR (12/23) Best - in - class real - world data driving increased Amtagvi adoption 1 AMTAGVI® IN PREVIOUSLY TREATED ADVANCED MELANOMA 1. Karapetyan L et al. Tandem Meetings 2026. 2. Three Prior Lines of Therapy (1L - 3L): 1L ipilimumab + nivolumab; 2L da

  12. Slide 12: Amtagvi Patient Journey

    12 © 2026, Iovance Biotherapeutics, Inc. 12 © 2026, Iovance Biotherapeutics, Inc. Lymphodepletion Reimbursement ~3 Weeks Manufacturing, Release & Shipment Short - Course Proleukin® Scheduling Goal: <2 weeks Primary Oncologist ATC Medical Oncologist Follow - Up & Return to Primary Oncologist ~ 32 DAY

  13. Slide 13: Manufacturing Facility Dedicated to Commercial and Clinical TIL Cell Therapies

    13 © 2026, Iovance Biotherapeutics, Inc. • Modular design • Global supply and logistics • C apacity for up to 5K patients/year • Optimal utilization , quality & COS Manufacturing Facility Dedicated to Commercial and Clinical TIL Cell Therapies COS = cost of sales Philadelphia, PA

  14. Slide 14: Amtagvi Authorized Treatment Centers (ATC)

    14 © 2026, Iovance Biotherapeutics, Inc. Amtagvi ® Authorized Treatment Centers (ATC) AMTAGVI® IN PREVIOUSLY TREATED ADVANCED MELANOMA 10K+ ≤ 100 Population 2 1. Not all authorized treatment centers are listed, Includes onboarded ATCs as well as in - process ATCs. 2. U.S. Census Bureau, 2024 Annual

  15. Slide 15: Broad Market Access

    15 © 2026, Iovance Biotherapeutics, Inc. Broad Market Access Data on file as of July 2025. *Plans or policies that cover Amtagvi, including pharmacy benefit managers (PBMs) Abbreviations: NCCN, National Comprehensive Cancer Network Payer medical coverage policies consistent with Amtagvi label, clini

  16. Slide 16: Amtagvi Expansion Plans in Advanced Melanoma

    16 © 2026, Iovance Biotherapeutics, Inc. 16 Amtagvi® Expansion Plans in Advanced Melanoma

  17. Slide 17: Unprecedented Rate, Depth & Durability of Responses in Frontline Advanced Melanoma

    17 © 2026, Iovance Biotherapeutics, Inc. Unprecedented Rate, Depth & Durability of Responses in Frontline Advanced Melanoma • Median PFS and median DOR not reached at nearly 2 years of median follow - up (median follow - up 21.7 months) • All response - evaluable patients demonstrated regression of

  18. Slide 18: TILVANCE-301 Global Phase 3 and Confirmatory Trial

    18 © 2026, Iovance Biotherapeutics, Inc. Option to crossover to lifileucel after BIRC - confirmed PD 1:1 Randomization TILVANCE - 301 Global Phase 3 and Confirmatory Trial LIFILEUCEL + PEMBROLIZUMAB IN FRONTLINE ADVANCED MELANOMA *Pembrolizumab in both arms is started at the same time after randomiz

  19. Slide 19: TIL Therapy Pipeline

    19 © 2026, Iovance Biotherapeutics, Inc. 19 TIL Therapy Pipeline

  20. Slide 20: Significant Unmet Need in 2L Nonsquamous NSCLC

    20 © 2026, Iovance Biotherapeutics, Inc. 1M+ Global Annual Deaths 1 Significant Unmet Need in 2L Nonsquamous NSCLC – Limited durability with SOC Chemo (Docetaxel) 2 5.6 mo mDOR 12.3 mo OS 12.8% ORR >90K Annual Deaths 1 1. Data on file as of November 2025, includes targeted patient population in pote

  21. Slide 21: IOV-LUN-202 Registrational Trial Design

    21 © 2026, Iovance Biotherapeutics, Inc. IOV - LUN - 202 Registrational Trial Design Phase 2 Multicenter Study of Lifileucel in Post - Anti - PD - 1 NSCLC (NCT04614103) Abbreviations: Anti - PD - 1, anti - programmed cell death inhibitor; IRC, independent review committee; NSCLC, non - small cell lu

  22. Slide 22: Fast Track Designation in Second-Line Nonsquamous mNSCLC

    22 © 2026, Iovance Biotherapeutics, Inc. Fast Track Designation in Second - Line Nonsquamous mNSCLC IOV - LUN - 202 COHORTS 1 & 2 POST - ANTI - PD - 1 ADVANCED NSCLC 1. Interim data cut as of October 10, 2025 of patients with nonsquamous NSCLC with minimum cell dose based on FDA feedback in me lan o

  23. Slide 23: Cohort 3A Results Support Adding TIL Therapy to Frontline NSCLC

    23 © 2026, Iovance Biotherapeutics, Inc. Cohort 3A Results Support Adding TIL Therapy to Frontline NSCLC 1 IOV - COM - 202 COHORT 3A, ICI - NAÏVE NSCLC % Change from Baseline Time (Months) Since TIL Infusion PD - L1 negative, EGFR WT subgroup has a high unmet need 2 Best Percentage Change from Basel

  24. Slide 24: Significant Market Opportunity for Advanced Soft Tissue Sarcomas

    24 © 2026, Iovance Biotherapeutics, Inc. 1.. CancerMPact Patient Metrics for US Soft Tissue Sarcoma (accessed February 2026); 2. Zhou et al. BMC Public Health 2025; 3. CancerMPact Treatment Architecture for Sarcoma for the US & EU5 (May 2025) to inform treatment rates in the US and EU5. 4. Parikh RC

  25. Slide 25: Potential Market for Advanced Endometrial Cancer

    25 © 2026, Iovance Biotherapeutics, Inc. 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. https://seer.cancer.gov (accessed August 2025); 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022; 3. NCCN Gui

  26. Slide 26: IOV-END-201 Phase 2 Proof of Concept Study Endometrial Cancer

    26 © 2026, Iovance Biotherapeutics, Inc. pMMR Subgroup dMMR Subgroup Endpoints • Primary : ORR per RECIST v1.1 by investigator • Secondary : CR rate , DOR, DCR, PFS, OS, safety and tolerability • Subgroup analyses specified in protocol • Potential to expand / convert to registrational trial • First

  27. Slide 27: IOV-4001: PD-1 Inactivated TIL Therapy

    27 © 2026, Iovance Biotherapeutics, Inc. 27 © 2026, Iovance Biotherapeutics, Inc. IOV - 4001: PD - 1 Inactivated TIL Therapy 2 T cell PD - 1 PD - 1 inhibits the ability of T cells to fight cancer: T cells, upon encountering cancer cells, produce PD - 1, a checkpoint receptor that is activated by pro

  28. Slide 28: Phase 1/2 Open-Label First-in-Human Study: IOV-GM1-201

    28 © 2026, Iovance Biotherapeutics, Inc. Phase 1/2 Open - Label First - in - Human Study: IOV - GM1 - 201 Endpoints • Phase 1: Safety (Complete) • Phase 2 Primary: ORR per RECIST v1.1 by investigator • Secondary : CR rate , DOR, DCR, PFS, OS, safety and tolerability Genetically Modified, PD - 1 Inac

  29. Slide 29: IOV-3001: Next Generation IL-2 for TIL Supportive Regimen

    29 © 2026, Iovance Biotherapeutics, Inc. 29 © 2026, Iovance Biotherapeutics, Inc. IOV - 3001: Next Generation IL - 2 for TIL Supportive Regimen 1,2 Phase 1/2 trial enrolling patients Recombinant fusion protein designed to enhance TIL survival and cellular proliferation • A modified copy of the codin

  30. Slide 30: IOV-5001: IL-12 TIL Therapy to Increase Efficacy

    30 © 2026, Iovance Biotherapeutics, Inc. IOV - 5001: IL - 12 TIL Therapy to Increase Efficacy 1. Zhang L, Rosenberg SA, et al, Clin Cancer Res 2015;21(10):2278 – 2288 2. Zhang L, Davis JS, et al, J Immunother Cancer 2020;8:e000210 3. Kobayashi M, Fitz L, et al, J Exp Med 1989;170:827 – 845. 4. Zeh H

  31. Slide 31: Corporate Summary

    31 © 2026, Iovance Biotherapeutics, Inc. 31 Corporate Summary

  32. Slide 32: Financial Position & Outlook

    32 © 2026, Iovance Biotherapeutics, Inc. 1. Includes anticipated revenue from Amtagvi® and Proleukin® and anticipated savings from strategic restructuring announced on Aug ust 7, 2025 2. Preferred shares are shown on an as - converted basis . Financial Position & Outlook Cash runway into Q3 2027 1 2

  33. Slide 33: Thank You

    33 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Thank You

Iovance Biotherapeutics — Investor Presentation (February 2026) on 6ix